Logo image
Monovalent SARS-CoV-2 mRNA vaccine does not boost Omicron-specific immune response in diabetic and control pediatric patients
Journal article   Open access   Peer reviewed

Monovalent SARS-CoV-2 mRNA vaccine does not boost Omicron-specific immune response in diabetic and control pediatric patients

Alan Sariol, Molly A Vickers, Shannon M Christensen, Daniela Weiskopf, Andrew W Norris, Michael J Tansey, Catherina T Pinnaro and Stanley Perlman
The Journal of infectious diseases, Vol.229(4), pp.1059-1067
04/12/2024
DOI: 10.1093/infdis/jiad366
PMCID: PMC11011175
PMID: 37624979
url
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011175View
Published (Version of record) Open Access

Abstract

While the immunogenicity of SARS-CoV-2 vaccines has been well described in adults, pediatric populations have been less studied. In particular, children with type 1 diabetes are generally at elevated risk for more severe disease after infections, but are understudied in terms of COVID-19 and SARS-CoV-2 vaccine responses. We investigated the immunogenicity of COVID-19 mRNA vaccinations in 35 children with type 1 diabetes (T1D) and 23 controls and found that these children develop levels of SARS-CoV-2 neutralizing antibody titers and spike protein-specific T cells comparable to non-diabetic children. However, in comparing the neutralizing antibody responses in children who received two doses of mRNA vaccines (24 T1D; 14 controls) with those who received a third, booster dose (11 T1D; 9 controls), we found that the booster dose increased neutralizing antibody titers against ancestral SARS-CoV-2 strains but, unexpectedly, not omicron lineage variants. In contrast, boosting enhanced omicron variant neutralizing antibody titers in adults.

Details

Metrics

Logo image